Cargando…
Linking hydroxychloroquine to hemolysis in a ‘suspected’ glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection – a critical appraisal
Autores principales: | Afra, T.P., Nampoothiri, Ram Vasudevan, Razmi T, Muhammed, Hafi, N. A. Bishurul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340024/ https://www.ncbi.nlm.nih.gov/pubmed/32651040 http://dx.doi.org/10.1016/j.ejim.2020.07.001 |
Ejemplares similares
-
Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?
por: Afra, TP, et al.
Publicado: (2020) -
Fulminant hemolysis in glucose‐6‐phosphate dehydrogenase deficiency
por: Moiz, Bushra, et al.
Publicado: (2017) -
Comorbid psoriasis-bipolar disorder successfully treated with apremilast: much more than a mere coincidence?
por: Uvais, N A, et al.
Publicado: (2020) -
Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out
por: De Franceschi, Lucia, et al.
Publicado: (2020) -
Hepatitis A Virus-induced Severe Hemolysis Complicated by Severe Glucose-6-Phosphate Dehydrogenase Deficiency
por: Sharma, Dhruva, et al.
Publicado: (2018)